NFKB1 and cancer: DSF can synergistically enhance gemcitabine cytotoxicity and reverse gemcitabine resistance in cancer cell lines through ROS induction and inhibition of the ALDH and NF-κB pathways (Liu et al., 2012; O'Brien et al., 2012).